Jakob Dupont - Dec 1, 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ David Tucker, Attorney-in-Fact for Jakob Dupont
Stock symbol
ATRA
Transactions as of
Dec 1, 2021
Transactions value $
-$41,789
Form type
4
Date filed
12/3/2021, 03:15 PM
Previous filing
Nov 18, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Options Exercise $47.9K +5K +5.52% $9.58 95.6K Dec 1, 2021 Direct F1
transaction ATRA Common Stock Sale -$89.7K -5K -5.23% $17.94* 90.6K Dec 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise $0 -5K -1.83% $0.00 268K Dec 1, 2021 Common Stock 5K $9.58 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021.
F2 The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.78 to $18.135. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.